T

here’s more than one way to attack PCSK9 and lower cholesterol, but investors seem to be losing hope that the field’s next generation of drugs will ever make a splash on the market.

The Medicines Company, which is years away from selling its PCSK9 drug, saw its share price tumble by about 15 percent on Friday despite presenting positive data, as Wall Street reacted to disappointing clinical results from Amgen’s approved Repatha that have changed the landscape in biotech.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Take your pick:

    -Repatha, lowers LDL cholesterol 59%, for $14,100/year.

    -Vytorin 10/40 (well tolerated), lowers LDL cholesterol 55%, for $25/month with coupon.

    No brainer.

  • This is where the rubber meets the road profit or professional medicine? Somehow I think I’d have a heart attack to hear Jean Luke’s reply when Beverly said we can’t cure WARF our stock holders won’t approve it..

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy